Data as of November 9, 2026 · Disclosed healthcare M&A transactions, 2018–2026
Did higher interest rates lower healthcare practice valuations?
Between March 2022 and July 2023 the Federal Reserve raised its policy rate from near zero to 5.25–5.50%, and it began cutting in September 2024. Owners often hear that this pushed down what buyers pay. Our deal data says that depends on the size of the deal.
For healthcare deals under $100M of enterprise value, the size most practices sell at, the median multiple barely moved: 7.0x EBITDA in the near-zero years, 6.9x during the hikes and 7.2x since cuts began. Large platform deals swung more.
Healthcare deals under $100M
| Deal years | Rates | Median EV/EBITDA | Middle half | Median deal size | Deals |
|---|---|---|---|---|---|
| 2018–2019 | Before the pandemic | 7.8x | 5.3x–11x | $18.4M | 122 |
| 2020–2021 | Near-zero rates | 7x | 5x–10.5x | $11.6M | 160 |
| 2022–2023 | Fastest hikes in decades | 6.9x | 5.1x–9.7x | $14.8M | 103 |
| 2024–2026 | Cuts begin (Sept 2024) | 7.2x | 5.3x–10.4x | $21.4M | 71 |
Healthcare deals of $100M and up
| Deal years | Rates | Median EV/EBITDA | Middle half | Median deal size | Deals |
|---|---|---|---|---|---|
| 2018–2019 | Before the pandemic | 12.5x | 9.6x–16.4x | $580M | 175 |
| 2020–2021 | Near-zero rates | 14.8x | 12x–18.5x | $750M | 204 |
| 2022–2023 | Fastest hikes in decades | 15.2x | 12x–20.5x | $730M | 152 |
| 2024–2026 | Cuts begin (Sept 2024) | 13.9x | 11x–18.6x | $612M | 153 |
Large-deal multiples rose through 2020–2023 and eased after rates peaked. These deals are usually financed with more debt, which is one reason they are more sensitive to borrowing costs.
Why the all-deal median misleads
| Deal years | Median EV/EBITDA | Middle half | Median deal size | Deals |
|---|---|---|---|---|
| 2018–2019 | 10.4x | 7.1x–15.3x | $193M | 297 |
| 2020–2021 | 12x | 7.3x–16.7x | $195M | 364 |
| 2022–2023 | 12x | 7.2x–17.1x | $230M | 255 |
| 2024–2026 | 12.2x | 8.2x–17.5x | $270M | 224 |
Across all disclosed healthcare deals the median rose from 10.4x to 12.2x. Over the same period the median deal got bigger, from about $193M to $270M. More large deals in the mix pull the overall median up even when the multiples within each size group are flat or falling. If someone quotes you a single “healthcare multiple,” ask what size of deal it comes from.
Common questions
Did rising interest rates lower what healthcare practices sell for?
Not for smaller deals in our data. Disclosed healthcare deals under $100M of enterprise value had a median of 7.0x EBITDA in 2020–2021, 6.9x in 2022–2023 and 7.2x in 2024–2026. Larger platform deals moved more: their median eased from 15.2x in 2022–2023 to 13.9x in 2024–2026.
Why do headline healthcare multiples look higher than before?
Mostly because the deals got bigger. The median disclosed healthcare deal rose from about $193M in 2018–2019 to $270M in 2024–2026, and bigger deals trade at higher multiples. Compare a practice with deals of its own size, not the all-deal median.
Will rate cuts raise the value of my practice?
Our data does not show small-practice multiples tracking rates closely. What moves an individual practice’s price far more is its own EBITDA, payer mix, growth, how much depends on the owner, and how many buyers compete for it.
What is your practice worth today?
The valuation compares your numbers with deals of your size and type, not the all-deal median.
Method: disclosed transactions (licensed M&A database, SEC EDGAR filings, verified press releases) with a reported EV/EBITDA between 0 and 60x, grouped by the year the deal was announced; 2026 is year to date. Size is enterprise value at the deal. Rate history: FRED, Federal Funds Effective Rate. Medians describe groups of deals, not any single business.